Switzerland: CSL to acquire Vifor Pharma for US$11.7bn

Australian-based global biotechnology company, CSL, has agreed to acquire Vifor Pharma, a specialty pharmaceutical company with leadership in iron deficiency, nephrology & cardio-renal therapies, for an aggregate equity value of US$11.7bn. The transaction remains subject to a minimum acceptance rate of 80% of all Vifor Pharma shareholders and regulatory approvals. Vifor’s Board is unanimously recommending…

You must be a HMI Subscriber to view this content.

Subscribe Now »